Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy

Immunological Reviews

Volumn 276, Issue 1, 2017, Pages 192-212

  Kean, Leslie S ^a,b,c   Turka, Laurence A ^d   Blazar, Bruce R ^e  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

co inhibitory blockade; co stimulation blockade; transplantation

Indexed keywords

ABATACEPT; CD2 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; GERMINAL CENTER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; TRANSPLANTATION TOLERANCE; TUMOR IMMUNOLOGY; ANIMAL; GENETICS; GRAFT REJECTION; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; ORGAN TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85014412248     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12523     Document Type: Review

References (338)

1. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med. 1993;178:1801–1806.
2. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257:792–795.
3. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992;257:789–792.
4. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561–569.
5. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434–438.
6. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today. 1990;11:211–216.
7. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA. 1990;87:5031–5035.
8. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714–2722.
9. Gimmi CD, Freeman GJ, Gribben JG, et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA. 1991;88:6575–6579.
10. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262:909–911.
11. Lenschow DJ, Su GH, Zuckerman LA, et al. Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA. 1993;90:11054–11058.
12. Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med. 1994;180:2049–2058.
13. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature. 1987;328:267–270.
14. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991;147:1037–1044.
15. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–413.
16. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459–465.
17. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA. 1992;89:11102–11105.
18. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994;265:1225–1227.
19. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995;96:987–993.
20. Racke MK, Scott DE, Quigley L, et al. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest. 1995;96:2195–2203.
21. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243–1252.
22. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470–1479.
23. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–1915.
24. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–1123.
25. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:2263–2271.
26. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006;144:865–876.
27. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology. 2008;71:917–924.
28. Parulekar AD, Boomer JS, Patterson BM, et al. A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med. 2013;187:494–501.
29. Orban T, Bundy B, Becker DJ, et al. Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recentonset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–419.
30. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012;143(62–9):e4.
31. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077–3087.
32. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83:3815–3825.
33. + T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood. 2010;116:5403–5418.
34. Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol. 1998;160:4225–4231.
35. Hakim FT, Cepeda R, Gray GS, June CH, Abe R. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J Immunol. 1995;155:1757–1766.
36. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. 1994;58:602–610.
37. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 1996;157:4258–4267.
38. Koura DT, Horan JT, Langston AA, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: A first-in-disease trial. Biol Blood Marrow Transplant. 2013;19:1638–1649.
39. Pree I, Bigenzahn S, Fuchs D, et al. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3-dioxygenase. Transplantation. 2007;83:663–667.
40. Blaha P, Bigenzahn S, Koporc Z, Sykes M, Muehlbacher F, Wekerle T. Shortterm immunosuppression facilitates induction of mixed chimerism and tolerance after bone marrow transplantation without cytoreductive conditioning. Transplantation. 2005;80:237–243.
41. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol. 2002;14:592–600.
42. Wekerle T, Kurtz J, Sayegh M, et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol. 2001;166:2311–2316.
43. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6:464–469.
44. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999;68:1348–1355.
45. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187:2037–2044.
46. Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001;167:1103–1111.
47. Adams AB, Pearson TC, Larsen CP. Conventional immunosuppression and costimulation blockade. Philos Trans R Soc Lond B Biol Sci. 2001;356:703–705.
48. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes. 2002;51:265–270.
49. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol. 2000;165:1–4.
50. Kean LS, Durham MM, Adams AB, et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002;99:1840–1849.
51. Kean LS, Manci EA, Perry J, et al. Chimerism and cure: Hematologic and pathologic correction of murine sickle cell disease. Blood. 2003;102:4582–4593.
52. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a highaffinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443–453.
53. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159:5187–5191.
54. Vincenti F, Larsen C, Durrbach A, et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353:770–781.
55. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–343.
56. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–2883.
57. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91:976–983.
58. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
59. Sansom DM. CD28, CTLA-4 and their ligands: Who does what and to whom? Immunology. 2000;101:169–177.
60. Schmidt EM, Wang CJ, Ryan GA, et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol. 2009;182:274–282.
61. + regulatory T cell function. Science. 2008;322:271–275.
62. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
63. + regulatory T cells. J Immunol. 2003;171:3348–3352.
64. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest. 2013;123:580–593.
65. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8:2086–2096.
66. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant. 2012;12:846–855.
67. Zheng HB, Watkins B, Tkachev V, et al. The knife's edge of tolerance: Inducing stable multilineage mixed chimerism but with a significant risk of CMV reactivation and disease in rhesus macaques. Am J Transplant. 2016; doi:10.1111/ajt.14006.
68. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028.
69. Hanke T. Lessons from TGN1412. Lancet. 2006;368:1569–1570; author reply 70.
70. Suchard SJ, Davis PM, Kansal S, et al. A monovalent anti-human CD28 domain antibody antagonist: Preclinical efficacy and safety. J Immunol. 2013;191:4599–4610.
71. + T cell responses by selective CD28 blockade is independent of reduced ICOS expression. PLoS ONE. 2015;10:e0130490.
72. + T cell responses. J Exp Med. 2014;211:297–311.
73. Shi R, Honczarenko M, Zhang S, et al. Pharmacokinetic, pharmacodynamic, and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects. J Clin Pharmacol. 2016; doi:10.1002/jcph.791.
74. Yang Z, Wang H, Salcedo TW, et al. Integrated pharmacokinetic/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-CD28 receptor antagonist BMS-931699. J Pharmacol Exp Ther. 2015;355:506–515.
75. Mary C, Coulon F, Poirier N, et al. Antagonist properties of monoclonal antibodies targeting human CD28: Role of valency and the heavy-chain constant domain. mAbs. 2013;5:47–55.
76. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab’ antibody. Am J Transplant. 2012;12:2630–2640.
77. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 monovalent fab’ antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15:88–100.
78. Vierboom MP, Breedveld E, Kap YS, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a nonhuman primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405–418.
79. Haanstra KG, Dijkman K, Bashir N, et al. Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis. J Immunol. 2015;194:1454–1466.
80. Ville S, Poirier N, Branchereau J, et al. Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection. J Am Soc Nephrol. 2016; doi:10.1681/ASN.2015070774.
81. Hippen KL, Watkins B, Tkachev V, et al. Preclinical testing of anti-human CD28 Fab’ antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD). Transplantation. 2016; doi:10.1097/TP.0000000000001465.
82. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–172.
83. Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptorassociated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38:10168–10177.
84. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med. 1993;178:1567–1575.
85. Van den Eertwegh AJ, Noelle RJ, Roy M, et al. In vivo CD40-gp39 interactions are essential for thymusdependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med. 1993;178:1555–1565.
86. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA. 1996;93:13967–13972.
87. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation. 1996;61:4–9.
88. + T cells, precluding a role for sustained regulation. Eur J Immunol. 2005;35:2679–2690.
89. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant. 2004;4:1391–1398.
90. Kurtz J, Shaffer J, Lie A, Anosova N, Benichou G, Sykes M. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: Evidence for anergy and deletion but not regulatory cells. Blood. 2004;103:4336–4343.
91. Niimi M, Pearson TC, Larsen CP, et al. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol. 1998;161:5331–5337.
92. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood. 2001;98:467–474.
93. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versushost disease lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102:473–482.
94. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29–39.
95. Smook ML, Heeringa P, Damoiseaux JG, et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis. 2005;183:275–282.
96. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest. 2004;114:979–987.
97. + regulatory T cells. J Immunol. 2005;174:6993–7005.
98. + T regulatory cell induction and function in transplant recipients after CD154 blockade is TLR4 independent. J Immunol. 2006;176:5988–5994.
99. + regulatory T cells are generated following CD40/CD154 blockade. Proc Natl Acad Sci USA. 2011;108:20701–20706.
100. Pinelli DF, Wagener ME, Liu D, et al. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am J Transplant. 2013;13:3021–3030.
101. Zhang N, Schroppel B, Lal G, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009;30:458–469.
102. Larsen CP, Page A, Linzie KH, et al. An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant. 2010;10:2396–2409.
103. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant. 2014;14:59–69.
104. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5:686–693.
105. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997;94:8789–8794.
106. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation. 2002;106:2111–2117.
107. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594.
108. Charafeddine AH, Kim EJ, Maynard DM, et al. Platelet-derived CD154: Ultrastructural localization and clinical correlation in organ transplantation. Am J Transplant. 2012;12:3143–3151.
109. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
110. Badell IR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant. 2012;12:126–135.
111. Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol. 2009;183:1625–1635.
112. Lowe M, Badell IR, Thompson P, et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant. 2012;12:2079–2087.
113. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol. 2001;166:322–329.
114. Thompson P, Cardona K, Russell M, et al. CD40specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 2011;11:947–957.
115. Page A, Srinivasan S, Singh K, et al. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHCdefined rhesus macaque transplant model. Am J Transplant. 2012;12:115–125.
116. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005;174:54250.
117. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation. 2003;75:637–643.
118. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation. 2002;74:933–940.
119. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant. 2009;9:1732–1741.
120. Imai A, Suzuki T, Sugitani A, et al. A novel fully human antiCD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation. 2007;84:1020–1028.
121. Xie JH, Yamniuk AP, Borowski V, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192:4083–4092.
122. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397:263–266.
123. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22:326–332.
124. Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409:97–101.
125. Gonzalo JA, Tian J, Delaney T, et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol. 2001;2:597–604.
126. Rottman JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol. 2001;2:605–611.
127. Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol. 2009;10:167–175.
128. Xu H, Li X, Liu D, et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature. 2013;496:523–527.
129. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature. 2001;409:102–105.
130. Schenk AD, Gorbacheva V, Rabant M, Fairchild RL, Valujskikh A. Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant. 2009;9:64–73.
131. Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol. 2001;2:591–596.
132. Nanji SA, Hancock WW, Luo B, et al. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes. 2006;55:27–33.
133. Nanji SA, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant. 2004;4:526–536.
134. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005;105:3372–3380.
135. Sato M, Storb R, Loretz C, et al. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graftversus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: A potential therapeutic target. Transplantation. 2013;96:34–41.
136. Ogawa S, Nagamatsu G, Watanabe M, et al. Opposing effects of anti-activation-inducible lymphocyteimmunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J Immunol. 2001;167:5741–5748.
137. Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123:3988–3998.
138. Lo DJ, Anderson DJ, Song M, et al. A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation. Am J Transplant. 2015;15:984–992.
139. Chen AI, McAdam AJ, Buhlmann JE, et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity. 1999;11:68998.
140. Kopf M, Ruedl C, Schmitz N, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity. 1999;11:699–708.
141. + T-cell mediated skin allograft rejection. Transplantation. 2010;90:1265–1271.
142. + T cells and regulatory T cells to alloantigen. J Immunol. 2013;191:1465–1475.
143. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood. 2000;95:2434–2439.
144. Blazar BR, Sharpe AH, Chen AI, et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood. 2003;101:3741–3748.
145. + (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2004;126:697–703.
146. Miura Y, Thoburn CJ, Bright EC, Arai S, Hess AD. Regulation of OX40 gene expression in graft-versus-host disease. Transplant Proc. 2005;37:57–61.
147. Moncrieffe H, Coles M, Stockinger B. The influence of CD4 T-cell subsets on control of CD4 T-cell-mediated graft-versus-host disease. Immunology. 2008;125:459–468.
148. Ge X, Brown J, Sykes M, Boussiotis VA. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemiaspecific effectors. Biol Blood Marrow Transplant. 2008;14:518–530.
149. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol. 2004;172:1691–1698.
150. + Tregs. Blood. 2007;110:2501–2510.
151. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9–15.
152. Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: Choose the right CAR for you. Curr Hematol Malig Rep. 2016;11:368–384.
153. + Treg. J Immunol. 2012;189:5985–5994.
154. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol. 1994;24:367–374.
155. Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150:771–781.
156. Dawicki W, Watts TH. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol. 2004;34:743–751.
157. Lee SW, Vella AT, Kwon BS, Croft M. Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J Immunol. 2005;174:6803–6808.
158. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47–55.
159. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol. 2001;166:3174–3183.
160. Blazar BR, Lees CJ, Martin PJ, et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol. 2000;165:4901–4909.
161. Martins SL, St John LS, Champlin RE, et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004;104:3429–3436.
162. + T cells. Blood. 2005;105:2206–2213.
163. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol. 1999;163:4833–4841.
164. Asai T, Choi BK, Kwon PM, et al. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice. Immunology. 2007;121:349–358.
165. + T cells. Am J Transplant. 2003;3:543–551.
166. Saiki H, Suzuki J, Kosuge H, et al. Blockade of the 4-1BB pathway attenuates graft arterial disease in cardiac allografts. Int Heart J. 2008;49:105–118.
167. Cho HR, Kwon B, Yagita H, et al. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int. 2004;17:351–361.
168. Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep. 2013;13:408.
169. Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013;14:1490–1500.
170. Joshi A, Bauer R, Kuebler P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006;46:10–20.
171. Calabrese LH, Molloy E, Berger J. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol. 2015;11:119–123.
172. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65:546–551.
173. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10:816–824.
174. Stoppa AM, Maraninchi D, Blaise D, et al. Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transpl Int. 1991;4:3–7.
175. Le Mauff B, Hourmant M, Rougier JP, et al. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation. 1991;52:291–296.
176. Blazar BR, Carroll SF, Vallera DA. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin. Blood. 1991;78:3093102.
177. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607–2618.
178. Tchorsh-Yutsis D, Hecht G, Aronovich A, et al. Pig embryonic pancreatic tissue as a source for transplantation in diabetes: Transient treatment with anti-LFA1, anti-CD48, and FTY720 enables long-term graft maintenance in mice with only mild ongoing immunosuppression. Diabetes. 2009;58:1585–1594.
179. Kwun J, Farris AB, Song H, Mahle WT, Burlingham WJ, Knechtle SJ. Impact of leukocyte function-associated antigen-1 blockade on endogenous allospecific T cells to multiple minor histocompatibility antigen mismatched cardiac allograft. Transplantation. 2015;99:2485–2493.
180. Ramsey H, Pilat N, Hock K, et al. Anti-LFA-1 or rapamycin overcome costimulation blockade-resistant rejection in sensitized bone marrow recipients. Transpl Int. 2013;26:206–218.
181. Kitchens WH, Haridas D, Wagener ME, Song M, Ford ML. Combined costimulatory and leukocyte functional antigen-1 blockade prevents transplant rejection mediated by heterologous immune memory alloresponses. Transplantation. 2012;93:997–1005.
182. Reisman NM, Floyd TL, Wagener ME, Kirk AD, Larsen CP, Ford ML. LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood. 2011;118:5851–5861.
183. Setoguchi K, Schenk AD, Ishii D, et al. LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant. 2011;11:923–935.
184. Kitchens WH, Larsen CP, Ford ML. Integrin antagonists for transplant immunosuppression: Panacea or peril? Immunotherapy. 2011;3:305–307.
185. Badell IR, Russell MC, Thompson PW, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120:4520–4531.
186. Posselt AM, Bellin MD, Tavakol M, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10:187080.
187. Wang Y, Li D, Jones D, et al. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:1513–1522.
188. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized openlabel multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7:1770–1777.
189. Beus JM, Hashmi SS, Selvaraj SA, et al. Heterologous immunity triggered by a single, latent virus in Mus musculus: Combined costimulation- and adhesion- blockade decrease rejection. PLoS ONE. 2013;8:e71221.
190. Anderson DJ, Lo DJ, Leopardi F, et al. Anti-leukocyte function-associated antigen therapy in a nonhuman primate renal transplant model of costimulation blockaderesistant rejection. Am J Transplant. 2016;16:1456–1464.
191. Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells. Am J Transplant. 2012;12:69–80.
192. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10:2082–2091.
193. Paul LC, Davidoff A, Benediktsson H, Issekutz TB. The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation. 1993;55:1196–1199.
194. Stegall MD, Ostrowska A, Haynes J, Karrer F, Kam I, Gill RG. Prolongation of islet allograft survival with an antibody to vascular cell adhesion molecule 1. Surgery. 1995;118:366–369; discussion 9–70.
195. Molossi S, Elices M, Arrhenius T, Diaz R, Coulber C, Rabinovitch M. Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest. 1995;95:2601–2610.
196. Yang H, Issekutz TB, Wright JR Jr. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation. 1995;60:71–76.
197. Shiohara T, Moriya N, Gotoh C, Saizawa K, Nagashima M. Locally administered monoclonal antibodies to lymphocyte function-associated antigen 1 and to L3T4 prevent cutaneous graft-vs-host disease. J Immunol. 1988;141:2261–2267.
198. Harning R, Pelletier J, Lubbe K, Takei F, Merluzzi VJ. Reduction in the severity of graft-versus-host disease and increased survival in allogenic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1 alpha and MALA-2. Transplantation. 1991;52:842–845.
199. Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol. 1995;155:3856–3865.
200. Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: Long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016;9:130–147.
201. Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053–1065.
202. Ueda H, Takahara S, Azuma H, Kusaka M, Suzuki S, Katsuoka Y. Effect of a novel immunosuppressant, FTY720, on allograft survival after renal transplant in rats. Eur Surg Res. 2000;32:279–283.
203. Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y. Group FTYPITS. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant. 2011;26:3802–3805.
204. Huu DL, Matsushita T, Jin G, et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum. 2013;65:1624–1635.
205. Taylor PA, Kelly RM, Bade ND, Smith MJ, Stefanski HE, Blazar BR. FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal. Biol Blood Marrow Transplant. 2012;18:134152.
206. Weckbecker G, Pally C, Beerli C, et al. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transpl Int. 2010;23:543–552.
207. Lopes CT, Gallo AP, Palma PV, Cury PM, Bueno V. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. Transplant Proc. 2008;40:856–860.
208. Taylor PA, Ehrhardt MJ, Lees CJ, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood. 2007;110:3480–3488.
209. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200–205.
210. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol. 1998;160:5493–5499.
211. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160:5037–5044.
212. Hashimoto D, Asakura S, Matsuoka K, et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol. 2007;37:271–281.
213. Lee RS, Kuhr CS, Sale GE, et al. FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigennonidentical unrelated canine model. Transplantation. 2003;76:1155–1158.
214. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 2003;111:659–669.
215. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101:2886–2893.
216. Xun CQ, Little MT, Zellmer E, et al. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation. 2002;73:310–313.
217. Murai M, Yoneyama H, Ezaki T, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol. 2003;4:15460.
218. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest. 1999;104:49–57.
219. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol. 2004;173:845–854.
220. Welniak LA, Wang Z, Sun K, et al. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol. 2004;32:318–324.
221. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graftversus-host disease. N Engl J Med. 2012;367:135–145.
222. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation. 1992;54:286–291.
223. + effector memory T cells based on CD2 expression. Am J Transplant. 2011;11:22–33.
224. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009;15:746–749.
225. Stenger EO, Chiang KY, Haight A, Qayed M, Kean L, Horan J. Use of alefacept for preconditioning in multiply transfused pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015;21:1845–1852.
226. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125:3285–3296.
227. Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:284–294.
228. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12:417–430.
229. Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447–3452.
230. Huynh A, DuPage M, Priyadharshini B, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol. 2015;16:188–196.
231. + Tregulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804–3812.
232. Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y. Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. Exp Hematol. 2006;34:802–808.
233. + Treg cells. Exp Hematol. 2006;34:66–71.
234. Brunstein CG, Miller JS, McKenna DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: Kinetics, toxicity profile, and clinical effect. Blood. 2016;127:104451.
235. Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol. 2011;23:462–468.
236. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3:83ra41.
237. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE. 2011;6:e15868.
238. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood. 2011;117:1061–1070.
239. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: Tools, trials and tribulations. Nat Rev Immunol. 2009;9:704–716.
240. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity. 2009;30:656–665.
241. Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638–644.
242. Martelli MF, Di Ianni M, Ruggeri L, et al. “Designed” grafts for HLA-haploidentical stem cell transplantation. Blood. 2014;123:967–973.
243. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–3928.
244. + regulatory T cells. Proc Natl Acad Sci USA. 2006;103:5460–5465.
245. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: New therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401–406.
246. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graftversus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–1150.
247. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–399.
248. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499.
249. + T cells: Costimulatory requirements and role in memory formation. J Immunol. 2001;167:3699–3707.
250. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant. 2002;2:501–509.
251. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: An overlooked barrier to tolerance. Immunol Rev. 2003;196:147–160.
252. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003;111:1887–1895.
253. Padovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of two T cell receptor alpha chains: Dual receptor T cells. Science. 1993;262:422–424.
254. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol. 2006;176:1394–1401.
255. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–3895.
256. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322.
257. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687.
258. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553.
259. Wang L, Han R, Hancock WW. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur J Immunol. 2007;37:2983–2990.
260. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol. 2005;174:6648–6656.
261. + T cells to transplanted tissue. J Immunol. 2008;181:5313–5322.
262. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:1272–1277.
263. Schilbach K, Schick J, Wehrmann M, et al. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers. Transplantation. 2007;84:214–222.
264. + T cells. Blood. 2011;117:1030–1041.
265. Fujiwara H, Maeda Y, Kobayashi K, et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol. 2014;193:2565–2573.
266. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol. 2005;174:3408–3415.
267. Yang J, Popoola J, Khandwala S, et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008;117:660–669.
268. Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011;187:1113–1119.
269. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–3029.
270. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122:3062–3073.
271. Asakura S, Hashimoto D, Takashima S, et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest. 2010;120:2370–2378.
272. Matte-Martone C, Venkatesan S, Tan HS, et al. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): Shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J Immunol. 2011;187:1653–1663.
273. Saha A, O'Connor RS, Thangavelu G, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642–2660.
274. Yi T, Li X, Yao S, et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J Immunol. 2011;186:2739–2749.
275. Deng R, Cassady K, Li X, et al. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol. 2015;194:560–574.
276. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–122.
277. Menzies AM, Johnson DB, Ramanujam S, et al. AntiPD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016; doi:10.1093/annonc/mdw443.
278. Krecke N, Zimmer A, Friesenhahn-Ochs B, Muller CS, Vogt T, Pfohler C. Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma. Dermatoendocrinol. 2016;8:e1199307.
279. Koelzer VH, Buser T, Willi N, et al. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016;4:47.
280. Koelzer VH, Rothschild SI, Zihler D, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—An autopsy study. J Immunother Cancer. 2016;4:13.
281. Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836–842.
282. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240.
283. Davids MS, Kim HT, Bachireddy P, et al. Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–153.
284. Singh AK, Porrata LF, Aljitawi O, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant. 2016;51:1268–1270.
285. Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donorderived CAR T cells. Curr Opin Hematol. 2015;22:509–515.
286. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–4139.
287. Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood. 2016;127:1361–1370.
288. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.
289. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
290. Okamura T, Fujio K, Sumitomo S, Yamamoto K. Roles of LAG3 and EGR2 in regulatory T cells. Ann Rheum Dis. 2012;71(Suppl 2):i96–i100.
291. + regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA. 2009;106:13974–13979.
292. Chen SY, Hsu WT, Chen YL, Chien CH, Chiang BL. Lymphocyte-activation gene 3(+) (LAG3(+)) forkhead box protein 3(-) (FOXP3(-)) regulatory T cells induced by B cells alleviates joint inflammation in collagen-induced arthritis. J Autoimmun. 2016;68:75–85.
293. + regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 2016;9:137–145.
294. Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS ONE. 2014;9:e86551.
295. Wang L, Fraser CC, Kikly K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005;35:428–438.
296. Ueno T, Yeung MY, McGrath M, et al. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. Eur J Immunol. 2012;42:2343–2353.
297. Veenstra RG, Flynn R, Kreymborg K, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015;125:3335–3346.
298. + regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur J Immunol. 2007;37:2117–2126.
299. Yamaura K, Watanabe T, Boenisch O, et al. In vivo function of immune inhibitory molecule B7-H4 in alloimmune responses. Am J Transplant. 2010;10:2355–2362.
300. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010;6:e1000947.
301. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37.
302. + T-cell function. Hepatology. 2010;52:1934–1947.
303. + T cell exhaustion during chronic viral infection. Immunity. 2007;27:670–684.
304. Brown DR, Calpe S, Keszei M, et al. Cutting edge: An NK cell-independent role for Slamf4 in controlling humoral autoimmunity. J Immunol. 2011;187:21–25.
305. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010;160:348–358.
306. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102–1110.
307. Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093–1101.
308. Veenstra RG, Taylor PA, Zhou Q, et al. Contrasting acute graft-versushost disease effects of TIM-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood. 2012;120:682–690.
309. Wang F, He W, Yuan J, et al. Activation of Tim-3Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol. 2008;19:12–19.
310. + alloreactive T cell and prolongs survival of skin graft. Cell Immunol. 2007;250:68–74.
311. He W, Fang Z, Wang F, et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation. 2009;88:782–790.
312. Boenisch O, D'Addio F, Watanabe T, et al. TIM-3: A novel regulatory molecule of alloimmune activation. J Immunol. 2010;185:5806–5819.
313. + Tregs. J Clin Invest. 2012;122:2395–2404.
314. Tao YF, Lin F, Yan XY, et al. Galectin-9 in combination with EX-527 prolongs the survival of cardiac allografts in mice after cardiac transplantation. Transplant Proc. 2015;47:2003–2009.
315. Cai L, Zhou H, Fang Z, et al. Galectin-9 in combination with rapamycin induces cardiac allograft tolerance in mice. Transplantation. 2013;96:379–386.
316. Shimmura-Tomita M, Wang M, Taniguchi H, Akiba H, Yagita H, Hori J. Galectin9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. PLoS ONE. 2013;8:e63620.
317. Chen Y, Fukuda T, Thakar MS, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy. 2011;13:1269–1280.
318. Graves SS, Stone D, Loretz C, et al. Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. Transplantation. 2009;88:317–322.
319. Graves SS, Stone DM, Loretz C, et al. Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: Tools for allogeneic transplantation. Transplantation. 2011;91:833–840.
320. Mathes DW, Hwang B, Graves SS, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation. 2011;92:1301–1308.
321. Rosinski SL, Storb R, Strong RK, et al. Anti-CD28 antibody-initiated cytokine storm in canines. Transplant Direct. 2015;1. doi:10.1097/TXD.0000000000000516.
322. Jochum C, Beste M, Zellmer E, Graves SS, Storb R. CD154 blockade and donorspecific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1 Gy total body irradiation. Biol Blood Marrow Transplant. 2007;13:164–171.
323. Kean LS, Singh K, Blazar BR, Larsen CP. Nonhuman primate transplant models finally evolve: Detailed immunogenetic analysis creates new models and strengthens the old. Am J Transplant. 2012;12:812–819.
324. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704–1714.
325. + effector memory T-cells. Br J Pharmacol. 2010;161:512–526.
326. Pallardy M, Hunig T. Primate testing of TGN1412: Right target, wrong cell. Br J Pharmacol. 2010;161:509–511.
327. Pitcher CJ, Hagen SI, Walker JM, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol. 2002;168:29–43.
328. Poirier N, Mary C, Le Bas-Bernardet S, et al. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. mAbs. 2014;6:697–707.
329. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA. 1999;96:8132–8137.
330. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation. 1995;59:256–262.
331. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donorspecific tolerance in cynomolgus monkeys. Transplantation. 1997;64:709–716.
332. Boumpas DT, Furie R, Manzi S, et al. Group BGLNT. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–727.
333. Johnson ZP, Eady RD, Ahmad SF, et al. Immunogenetic Management Software: A new tool for visualization and analysis of complex immunogenetic datasets. Immunogenetics. 2012;64:329–336.
334. Wiseman RW, Karl JA, Bimber BN, et al. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat Med. 2009;15:1322–1326.
335. Zimin AV, Cornish AS, Maudhoo MD, et al. A new rhesus macaque assembly and annotation for next-generation sequencing analyses. Biol Direct. 2014;9:20.
336. Furlan SN, Watkins B, Tkachev V, et al. Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and man. Blood. 2016; doi:10.1182/blood-2016-07-726547.
337. Furlan SN, Watkins B, Tkachev V, et al. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015;7:315ra191.
338. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172:603–606.